1. The role of statins as therapeutic agents in cancer
- Author
-
Jan Strnadel, Henrieta Škovierová, Janka Sopková, Erika Halasova, and Eva Vidomanová
- Subjects
0301 basic medicine ,Male ,Physiology ,Angiogenesis ,Carcinogenesis ,Biophysics ,Mevalonic Acid ,Reductase ,medicine.disease_cause ,Models, Biological ,Metastasis ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Neoplasms ,medicine ,Humans ,Evidence-Based Medicine ,Dose-Response Relationship, Drug ,business.industry ,Cell growth ,Cholesterol ,nutritional and metabolic diseases ,Cancer ,General Medicine ,medicine.disease ,030104 developmental biology ,Treatment Outcome ,chemistry ,030220 oncology & carcinogenesis ,Cancer cell ,Cancer research ,lipids (amino acids, peptides, and proteins) ,Female ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,business - Abstract
Statins are the inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. This enzyme catalyzes conversion of HMG-CoA to mevalonate, which are the intermediates in cholesterol biosynthetic pathway. Statins also play an important role in carcinogenesis, because they are able to affect the cancer cell metabolism. Their effect has been observed in several cellular processes, such as angiogenesis, metastasis, apoptosis and cell proliferation. However, these effects are highly dependent on type of cancer and individual statins vary in their antitumor potential. This review summarizes the recent epidemiological evidence and preclinical studies that showed effects of all clinically used statins in vitro and in vivo. We also consider the results of different observational and retrospective studies focused on association among statins and cancer risk which are still under open discussion.
- Published
- 2018